The Use of Very-Low-Dose Methadone and Haloperidol for Pain Control in the Hospital Setting: A Preliminary Report

Journal of Palliative Medicine

Volumn 18, Issue 2, 2015, Pages 114-119

  Salpeter, Shelley R ^a   Buckley, Jacob S ^b   Buckley, Nicholas S ^c   Bruera, Eduardo ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c Touro University College of Pharmacy and School of Osteopathic Medicine   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; METHADONE; OPIATE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CONSULTATION; FEMALE; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PAIN; PALLIATIVE THERAPY; DOSE RESPONSE; EVALUATION STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CALIFORNIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; PAIN; PAIN MANAGEMENT; PALLIATIVE CARE; RETROSPECTIVE STUDIES;

EID: 84921856114     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2014.0266     Document Type: Article

References (58)

1. Li JM: Pain management in the hospitalized patient. Med Clin North Am 2008;92:371-385, ix.
2. Koppert W, Sittl R, Scheuber K, et al.: Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003;99:152-159.
3. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 2: Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001;21: 255-264.
4. Simonnet G, Rivat C: Opioid-induced hyperalgesia: Abnormal or normal pain? Neuroreport 2003;14:1-7.
5. Mercadante S, Ferrera P, Villari P, et al.: Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-775.
6. Sotgiu ML, Valente M, Storchi R, et al.: Cooperative Nmethyl-D-Aspartate (NMDA) receptor antagonism and muopioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 2009;60:284-290.
7. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
8. Mercadante S: Switching methadone: A 10-year experience of 345 patients in an acute palliative care unit. Pain Med 2012;13:399-404.
9. Rhondali W, Tremellat F, Ledoux M: Methadone rotation for cancer patients with refractory pain in a palliative care unit: An observational study. J Palliat Med 2013;16:1382-1387.
10. De Conno F, Groff L, Brunelli C, et al.: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14: 2836-2842.
11. Gagnon B, Almahrezi A, Schreier G: Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8: 149-154.
12. Doverty M, White JM, Somogyi AA, et al: Hyperalgesic responses in methadone maintenance patients. Pain 2001;90: 91-96.
13. Chien CC, Pasternak GW: Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 1995;190:137-139.
14. Ishiwata K, Kawamura K, Kobayashi T, et al.: Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands. Nucl Med Biol 2003;30:429-434.
15. Cendan CM, Pujalte JM, Portillo-Salido E, et al.: Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl) 2005;182: 485-493.
16. Colclough G, McLarney JT, Sloan PA, et al.: Epidural haloperidol enhances epidural morphine analgesia: three case reports. J Opioid Manag 2008;4:163-166.
17. Entrena JM, Cobos EJ, Nieto FR, et al.: Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: Role of sigma-1 receptors. Psychopharmacology (Berl) 2009;205: 21-33.
18. Leong LB, Kelly AM: Are butyrophenones effective for the treatment of primary headache in the emergency department? CJEM 2011;13:96-104.
19. Seidel S, Aigner M, Ossege M, et al.: Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2013;8:CD004844.
20. Salpeter SR, Buckley JS, Bruera E: The use of very-lowdose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med 2013;16: 616-622.
21. Hjermstad MJ, Fayers PM, Haugen DF, et al.: Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage 2011;41:1073-1093.
22. National Institutes of Health Warren Grant Magnuson Clinical Center: Pain Intensity Instruments. July 2003. http://painconsortium.nih.gov/pain-scales/numericratingscale.pdf (Last accessed November 11, 2012).
23. AAHPM: Key principles of opioid administration. http://www.aahpm.org/pdf/equianalgesictable.pdf (Last accessed February 17, 2014).
24. Dalal S, Bruera E: Assessing cancer pain. Curr Pain Headache Rep 2012;16:314-324.
25. Herzig SJ, Rothberg MB, Cheung M, et al.: Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. J Hosp Med 2014;9:73-81.
26. Zimmermann C, Seccareccia D, Booth CM, et al.: Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005;19:25-31.
27. Pollock AB, Tegeler ML, Morgan V, et al.: Morphine to methadone conversion: An interpretation of published data. Am J Hosp Palliat Med 2011;28:135-140.
28. Mercadante S, Caraceni A: Conversion ratios for opioid switching in the treatment of cancer pain: A systematic review. Palliat Med 2011;25:504-515.
29. Mercadante S, Bruera E: The effect of age on opioid switching to methadone: A systematic review. J Palliat Med 2012;15:347-351.
30. Mancini I, Lossignol DA, Body JJ: Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 2000;12:308-313.
31. Pappagallo M, Dickerson ED, Hulka S: Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses. Am J Hosp Palliat Care 2000;17:407-413.
32. Azoulay D, Jacobs JM, Cialic R, et al.: Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc 2011;12:129-134.
33. Bennett MI, Graham J, Schmidt-Hansen M, et al.: Prescribing strong opioids for pain in adult palliative care: Summary of NICE guidance. BMJ 2012;344:e2806.
34. Caraceni A, Hanks G, Kaasa S, et al.: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 2012;13: e58-e68.
35. Khan MI, Walsh D, Brito-Dellan N: Opioid and adjuvant analgesics: Compared and contrasted. Am J Hosp Palliat Care 2011;28:378-383.
36. Lawlor P, Walker P, Bruera E, et al.: Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997;13:356-361.
37. Strasser F, Walker P, Bruera E: Palliative pain management: When both pain and suffering hurt. J Palliat Care 2005;21:69-79.
38. Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2005;22:291-294.
39. Daeninck PJ, Bruera E: Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 1999;43:924-938.
40. Vorobeychik Y, Chen L, Bush MC, et al.: Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008;9:724-727.
41. Baron MJ, McDonald PW: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2:277-282.
42. Mao J, Price DD, Mayer DJ: Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995;62:259-274.
43. Ossipov MH, Lai J, King T, et al.: Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004;61:126-148.
44. Chang G, Chen L, Mao J: Opioid tolerance and hyperalgesia. Med Clin North Am 2007;91:199-211.
45. Gilson AM, Ryan KM, Joranson DE, et al.: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;28:176-188.
46. Oderda GM, Gan TJ, Johnson BH, et al.: Effect of opioidrelated adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother 2013;27:62-70.
47. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manag. 2001;21:338-354.
48. Silverman SM: Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 2009;12: 679-684.
49. Scott CC, Chen KK: The action of 1,1-Diphenyl-1-(Dimethylaminoisopropyl)-butanone-2, a potent analgesic agent. J Pharm Exp Therap 1946;87:63-71.
50. Curry EA, Palla S, Hung F, et al.: Prescribing patterns and purchasing costs of long-Acting opioids over nine years at an academic oncology hospital. Am J Health Syst Pharm 2007;64:1619-1625.
51. Toombs JD, Kral LA: Methadone treatment for pain states. Am Fam Physician 2005;71:1353-1358.
52. Stevens RA, Ghazi SM: Routes of opioid analgesic therapy in the management of cancer pain. Cancer Control 2000;7: 132-141.
53. Yang C, Chen Y, Tang L, et al.: Haloperidol disrupts opioid-Antinociceptive tolerance and physical dependence. J Pharmacol Exp Ther 2011;338:164-172.
54. Ansari I, Yaghoutpoor E, Kiasalari Z, et al.: Methadone and haloperidol combination effect on the acquisition and expression of morphine tolerance and dependence in male mice. Basic Clin Pathophysiol 2013;1:15-22.
55. Honkaniemi J, Liimatainen S, Rainesalo S, et al.: Haloperidol in the acute treatment of migraine: A randomized, double-blind, placebo-controlled study. Headache 2006;46: 781-787.
56. Food and Drug Administration: Information for healthcare professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). 2007. www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsand providers/drugsafetyinformationforheathcareprofessionals/ucm085203.htm (Last accessed March 7, 2014).
57. Parsons HA, de la Cruz M, El Osta B, et al.: Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520-528.
58. Mercadante S, Casuccio A, Fulfaro F, et al.: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001;19:2898-2904